Trial Profile
Bevacizumab + RG1415 (erlotinib hydrochloride) combination therapy and the non-blind, randomized comparison to compare the RG1415 monotherapy Phase II clinical trials as a primary therapy for non-small-cell lung cancer patients with EGFR gene mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Bevacizumab
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 05 Jun 2018 Survival follow-up results (as of 31 Oct 2017) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 17 Oct 2017 Updated safety results published in the Drug Safety
- 08 Jun 2016 Results published in a Roche media release.